Education
About Us
Working with TipRanks
Follow Us
BBC - ETF AI Analysis
Top Page
Virtus LifeSci Biotech Clinical Trials ETF (BBC)
Rating:48Neutral
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has shown strong gains over the past three months and solid year-to-date results, indicating positive recent momentum.
Top Holdings Showing Robust Gains
Many of the largest positions, such as Erasca, Corvus Pharmaceuticals, and Alumis, have delivered strong year-to-date performance, helping drive the fund’s returns.
Focused Exposure to Health Care Innovation
With most assets in health care and clinical-stage biotech companies, the fund offers targeted exposure to a high-growth, innovation-driven area of the market.
Negative Factors
High Expense Ratio
The fund’s expense ratio is relatively high for an ETF, which can eat into long-term returns compared with lower-cost options.
Concentrated Sector Risk
Nearly all assets are in the health care sector, so the ETF is heavily exposed to swings in biotech and clinical trial news rather than being broadly diversified across industries.
Limited Geographic Diversification
The ETF is almost entirely invested in U.S. companies, offering little geographic diversification if the U.S. market or domestic biotech sector faces challenges.
BBC Historical Chart
AUM36.75M
RegionNorth America
Expense Ratio0.79%
Beta1.40
IssuerVirtus
Inception DateDec 16, 2014
Dividend Yield1.56%
Asset ClassEquity
Index TrackedLifeSci Biotechnology Clinical Trials Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume21,467
30 Day Avg. Volume27,092
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
75.93Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering126
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
BBC Summary
The Virtus LifeSci Biotech Clinical Trials ETF (BBC) tracks the LifeSci Biotechnology Clinical Trials Index and focuses on U.S. healthcare companies running drug and treatment trials. It mainly holds smaller biotech names, such as Intellia Therapeutics and Revolution Medicines, that are working on new, cutting-edge therapies. An investor might consider BBC if they want targeted exposure to potential long-term growth in medical innovation rather than broad market exposure. However, this ETF is concentrated in early-stage biotech stocks, which can be very volatile and may go up or down sharply with trial results and market sentiment.
How much will it cost me?The Virtus LifeSci Biotech Clinical Trials ETF (Ticker: BBC) has an expense ratio of 0.79%, which means you’ll pay $7.90 per year for every $1,000 invested. This is higher than average because the fund is actively managed, focusing on a specialized niche in the biotechnology sector that requires more research and expertise.
What would affect this ETF?The Virtus LifeSci Biotech Clinical Trials ETF could benefit from advancements in biotechnology and medical research, as well as increased funding for healthcare innovation in the U.S., where it is primarily focused. However, it may face challenges from regulatory hurdles, high costs associated with clinical trials, and potential setbacks in drug approvals, which could negatively impact the performance of its top holdings. Economic conditions, such as changes in interest rates or reduced investor appetite for high-risk sectors, could also influence the ETF's future performance.
BBC Top 10 Holdings
This ETF is a pure play on U.S. clinical-stage biotech, so a handful of volatile drug developers are steering the ship. Recent strength from names like Erasca, Corvus Pharmaceuticals, and Alumis has been helping the fund, as optimism around their pipelines gives the portfolio a bit of lift. On the other side, stocks such as Intellia Therapeutics and Rezolute have shown more mixed or lagging action, occasionally weighing on returns. With nearly everything tied to early-stage health care, performance lives and dies by clinical trial headlines rather than broad market trends.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Erasca | 2.20% | $830.30K | $3.25B | 502.84% | 34 Underperform | |
| Corvus Pharmaceuticals | 1.87% | $706.14K | $1.73B | 313.81% | 41 Neutral | |
| Alumis Inc. | 1.72% | $647.79K | $3.06B | 255.11% | 43 Neutral | |
| Rezolute | 1.34% | $507.11K | $309.71M | -38.17% | 53 Neutral | |
| Ventyx Biosciences | 1.27% | $480.21K | $1.00B | 646.52% | 41 Neutral | |
| Enliven Therapeutics | 1.25% | $470.69K | $1.57B | 28.63% | 36 Underperform | |
| RAPT Therapeutics | 1.17% | $441.60K | $1.60B | 532.46% | 39 Underperform | |
| CytomX Therapeutics | 1.08% | $409.47K | $964.09M | 625.00% | 66 Neutral | |
| Definium Therapeutics | 1.08% | $409.25K | $1.66B | 147.35% | 40 Neutral | |
| Intellia Therapeutics | 1.08% | $407.90K | $1.52B | 36.90% | 47 Neutral |
BBC Technical Analysis
Positive
―
Price Trends
38.91
Positive
33.67
Positive
26.83
Positive
Market Momentum
1.01
Positive
57.12
Neutral
35.53
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For BBC, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 40.75, equal to the 50-day MA of 38.91, and equal to the 200-day MA of 26.83, indicating a bullish trend. The MACD of 1.01 indicates Positive momentum. The RSI at 57.12 is Neutral, neither overbought nor oversold. The STOCH value of 35.53 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BBC.
BBC Peer Comparison
Comparison Results
Performance Comparison
BBC
Virtus LifeSci Biotech Clinical Trials ETF
41.92
19.24
84.83%
XHS
SPDR S&P Health Care Services ETF
―
―
―
LFSC
F/M Emerald Life Sciences Innovation ETF
―
―
―
IBBQ
Invesco Nasdaq Biotechnology ETF
―
―
―
BBP
Virtus LifeSci Biotech Products ETF
―
―
―
FTXH
First Trust Nasdaq Pharmaceuticals ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents